Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
Clinical trial NCT03113760 · COMPLETED
Trial details
- NCT number
- NCT03113760
- Sponsor
- AB2 Bio Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-21
- Primary completion
- 2023-10-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.